Literature DB >> 21953428

[Current treatment of locally advanced and metastatic prostate cancer].

Anton Ponholzer1, Ferdinand Steinbacher, Stephan Madersbacher, Paul Schramek.   

Abstract

Despite the broad use of PSA-testing in western medicine, still an estimated 1/3 of carcinomas of the prostate (PC) are diagnosed in a locally advanced or metastatic stage. In the current treatment-algorithm for locally advanced PC, radical prostatectomy, external beam radiation therapy (with and without hormonal therapy) and primary androgen deprivation are available. In fact, in a majority of patients treatment of this tumor stage will be a multimodal approach, which has to be discussed individually. For metastatic PC hormonal deprivation therapy is still the gold standard. Beside LHRH-agonists, surgical castration and complete androgen deprivation today LHRH-antagonists represent the different therapeutic options in this tumor stage. Effects on natural course of this disease have to be balanced to the side effects of long-term therapy. Castration-resistant PC is not the object of this overview even though there are a variety of new medical interventions emerging for the treatment of this stage of PC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953428     DOI: 10.1007/s10354-011-0014-7

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  18 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

Authors:  Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

3.  Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

Authors:  Chao-Yu Hsu; Steven Joniau; Raymond Oyen; Tania Roskams; Hein Van Poppel
Journal:  Eur Urol       Date:  2006-06-09       Impact factor: 20.096

4.  Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality.

Authors:  C Vutuc; T Waldhoer; S Madersbacher; M Micksche; G Haidinger
Journal:  Eur J Cancer Prev       Date:  2001-10       Impact factor: 2.497

5.  Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

Authors:  Christian Vutuc; Eva S Schernhammer; Gerald Haidinger; Thomas Waldhör
Journal:  Wien Klin Wochenschr       Date:  2005-07       Impact factor: 1.704

6.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005.

Authors:  Danil V Makarov; Bruce J Trock; Elizabeth B Humphreys; Leslie A Mangold; Patrick C Walsh; Jonathan I Epstein; Alan W Partin
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

7.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

8.  [The role of surgery in locally advanced prostate cancer].

Authors:  R-J Palisaar; J Noldus
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

9.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Authors:  Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

Review 10.  Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Authors:  Per-Anders Abrahamsson
Journal:  Eur Urol       Date:  2009-08-07       Impact factor: 20.096

View more
  1 in total

1.  Mechanism and Function of Angiogenin in Prostate Cancer.

Authors:  Nil Vanli; H U Guo-Fu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.